ECRG4 and gastric cancer: Further research revealed that ECRG4 was down-regulated to varying degrees in gastric cancer (14, 15), breast cancer (16, 17), hepatocellular cancer (18, 19), nasopharyngeal cancer (20–22), laryngeal cancer (23), bladder cancer (24, 25), glioma (26), colorectal cancer and prostate cancer (26–28).